The P-450 System: Definition and Relevance to the Use of Antidepressants in Medical Practice

Archives of Family Medicine

Volumn 5, Issue 7, 1996, Pages 406-412

  Goldberg, Richard J ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450;

AGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; HUMAN; REVIEW;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS;

EID: 0030188503     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.5.7.406     Document Type: Review

References (104)

1. Wrighton S, Stevens J. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1-21.
2. Guengerich F. Human cytochrome, P-450 enzymes. Life Sci. 1992;50:1471-1478.
3. Nebert D, Nelson D, Adesnik M. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA Seq. 1989;8:1-13.
4. Nelson D, Kamataki T, Wasman D. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1-51.
5. Murray M, Reidy G. Selectivity in the inhibition of mammalian cytochromes P450 by chemical agents. Pharmacol Rev. 1990;42:85-101.
6. Lledo P, Abrams S, Johnson A. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur J Clin Pharmacol. 1993;44:63-67.
7. Nakamura K, Goto F, Ray W, McAllister C, Jacqz E, Wilkinson G. Interethnic difference in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38:402-408.
8. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet. 1990;18:220-239.
9. Wedlund P, Aslanian W, McAllister C, Wilkinson G, Branch R. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984;36:773-780.
10. Butler M, Lang N, Young J, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2: 116-127.
11. Sanz E, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther. 1989;45:495-499.
12. Preskorn S. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med. 1993;94(suppl 5A):2S-12S.
13. Tsujimoto G, Hashimoto K, Hoffman B. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age: part 2. Int J Clin Pharmacol Ther Toxicol. 1989;27:102-116.
14. Hunt C, Westerkam W, Stave G, Wilson G. Hepatic cytochrome P-4503A activity in the elderly. Mech Ageing Dev. 1992;64:189-199.
15. Pollock B, Perel J, Kirshner M, Altieri L, Yeager A, Reynolds C. Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol. 1991;40:609-611.
16. Pollock BG, Perel JM, Altieri L, Kirshner M, Yeager A, Reynolds C. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull. 1992;28:163-168.
17. Brosen K, Skejlbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6: the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol. 1991;32:136-137.
18. Crewe H, Lennard M, Tucker G. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYPD6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262-265.
19. von Moltke L, Greenblatt D, Court M. Inhibition of aprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
20. Otton S, Crewe H, Lennard M, Tucker G, Woods H. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
21. Ujhelyi M, O'Rangers E, Fan C, Kluger J, Pharand C, Chow M. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. Clin Pharmacol Ther. 1993;53: 38-48.
22. Greene D, Dockens R, Salazar D. Coadministration of nefazodone and benzodiazepines, I: pharmacokinetic assessment. Clin Pharmacol Ther. 1994;55:141. Abstract.
23. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and humans. Int J Clin Pharmacol Res. 1983;111:449-458.
24. Honig P, Wortham D, Zamani K, Cantilena L. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 1994;7:148-156.
25. Knodell R, Holtzman J, Crankshaw D, Steele N, Stanley L. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology. 1982;82:84-88.
26. Honig P, Wortham D, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
27. Crane J, Shih H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med. 1993;95: 445-446.
28. Canafax D, Graves N, Hilligoes D. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation. 1991;51: 1014-1018.
29. Joblin M. Possible interaction of sertraline with carbamazepine. N Z Med J. 1994;107:43.
30. Greenblatt D, Preskorn S, Cotreau M, Horst W, Harunatz J. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486.
31. Lemberger L, Rowe H, Bosomworth J, Tenbarge J, Bergstrom R. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988;43:412-419.
32. Lasher T, Fleishaker J, Steenwyck R, Antal E. Pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl). 1991;104:323-327.
33. Grimsley S, Jann M, Carter J. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50:10-15.
34. Swims M. Potential terfenadine-fluoxetine interaction. Ann Pharmacother. 1993;27:1404-1405.
35. Brosen K, Skjelbo E, Rasmussen B. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214.
36. Fuhr U, Anders E, Mahr G. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992;36:942-948.
37. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry. 1992;55:412-413.
38. Woods DJ, Coulter DM, Pilands P. Interaction of phenytoin and fluoxetine. N Z Med J. 1994; 107:19.
39. Nightingale S. Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. JAMA. 1994; 271:1067.
40. Skejelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992;34:256-261.
41. Bloomer J, Woods F, Haddock R. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;25:521-523.
42. Otton S. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther. 1993;53:401-409.
43. Preskorn S. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34.
44. Bell I, Cole J. Fluoxetine induced elevation of desipramine levels and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol. 1988;8:447-448.
45. Lydiard R, Anton R, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry. 1993;150:1125-1126.
46. Vandel S, Bertschy G, Bonin B. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology. 1992;25:202-207.
47. Klamerus K, Maloney K, Rudolph R, Sisenwine S, Jusko W, Chiang S. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724.
48. Rosenblatt J, Rosenblatt N. More about spontaneous post marketing reports of bupropion-related seizures. Curr Affect Illness. 1992;11:18-20.
49. Goff D, Midha K, Brotman A. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry. 1991;148: 790-792.
50. Llerena A, Alm C, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-97.
51. Malek-Ahmadi P, Allen S. Paroxetine-molindone interaction. J Clin Psychiatry. 1995; 56:82-83.
52. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.
53. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenboughs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos. 1993;21: 1134-1141.
54. Fisher V, Vogels B, Maurer G, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal cytochrome P4502D6. J Pharmacol Exp Ther. 1992;260:1355-1360.
55. Funck-Brentano C, Thomas G, Jacqa-Aigrain E. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther. 1992;263:780.
56. Lee J, Kroemer H, Silberstein D, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990;322:1764-1768.
57. Lennard M, Silas J, Freestone S, et al. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-1560.
58. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun. 1988;152:411-416.
59. Sindrup S, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990; 48:686-693.
60. Hansen T. Interaction of fluoxetine and pentazocine. Am J Psychiatry. 1990;147:949-950.
61. Schadel M, Wu D, Otton S, Kalow W, Sellers E. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15:263-269.
62. Kivisto K, Neuvonen P, Klotz U. Inhibition of terfenadine metabolism. Clin Pharmacokinet. 1994;27:1-5.
63. von Moltke L, Greenblatt DJ, Cotreau-Bibbo M, Duan S, Hamartz J, Shader R. Inhibition of desipramine hydoxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Pharmacol Exp Ther. 1994;268:1278-1283.
64. Propulsid [product insert]. Titusville, NJ: Janssen Pharmaceutica Inc; 1995.
65. Lemoine A, Gauthier J, Azoulay D. Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P4503A4 in human liver. Mol Pharmacol. 1993;43:827-832.
66. Guengerich F, Martin M, Beaune P. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation: a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986; 261:5051-5060.
67. Prichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochrome P-450 IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711-719.
68. von Moltke L, Greenblatt D, Harmatz J, Shader R. Cytochromes in psychopharmacology. J Clin Psychopharmacol. 1994;14:1-4.
69. Mani C, Pearce R, Parkinson A. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 1994; 15:2716-2720.
70. Kerr B, Thummel K, Wurden C. Human liver carbamazepine metabolism: roles of CYP3A4 and CYP2C8 in 10, 11 epoxide formation. Biochem Pharmacol. 1994;47:1968-1979.
71. Henricsson S, Lindholm A, Aravogolou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol. 1990;66:49-52.
72. Waxman D, Attisano C, Guengerich F, Lapenson D. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6B-hydoxylase cytochrome P450 enzyme. Arch Biochem Biophys. 1988;263:424-436.
73. Pollak B. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994;2:204-213.
74. von Moltke L, Greenblatt D, Harmatz J, Shader R. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology. 1993;47:268-276.
75. Kronbach T, Mathys D, Umeno M. Oxidation of midazolam and triazolam by human cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89-96.
76. Varhe A, Olkkola K, Neuvonen P. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56:601-607.
77. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther. 1994;56:471-476.
78. Fleishaker J, Hulst L. Effect of fluvoxamine on the pharmacokinetics and phrmacodynamics of alprazolam in healthy volunteers. Pharm Res. 1992;9(suppl):S292.
79. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 1994;14:279-281.
80. Daniel D, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol. 1994;14:340-343.
81. Cognex [product monograph]. Morris Plains, NJ: Parke-Davis; 1993.
82. Sesardic D, Boobis A, Edwards R. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-demethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 1988;26:363-372.
83. Campbell M, Grant D, Inaba T. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarboninducible cytochrome P450 in human liver microsomes. Drug Metab Dispos. 1987;15:237-248.
84. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32:313-334.
85. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinetics. 1993;24:203-220.
86. Bertschy G. Probable metabolic interaction between methadone and fluvoxamine in addicted patients. Ther Drug Monit. 1994;16:42-45.
87. DeVane L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55:38-45.
88. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYPsC19 is the major (s)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 1994;33:1743-1752.
89. Bertilsson L, Hentorn T, Sanz E, Tybring G, Säwe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-355.
90. Abernethy D, Greenblatt D, Shader R. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther. 1985;232:183-188.
91. Wart SA, Walle T, Walle U, Wilkinson GR, Branch R. Propranolol's metabolism is determined by both mephytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther. 1989;45:72-79.
92. Knodell RG, Hall SD, Wilkinson GR, Guengerich F. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther. 1987;241:1112-1119.
93. Smith D, Jones B. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992;44:2089-2098.
94. Maurer PM, Bartkowski RB. Drug interactions of clinical significance with opioid analgesics, Drug Saf. 1993;8:30-48.
95. Woolsey R, Chen Y, Freiman J, Gillis RA. Mechanism of the cardiotoxic action of terfenadine. JAMA. 1993;269:1532-1539.
96. Monahan B, Ferguson C, Killeavy E. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
97. Drake W, Gordon G. Heart block in a patient on propranolol and fluoxetine. Lancet. 1994; 343:425-426.
98. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet. 1993;341:967-968.
99. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-depressed cytochrome P-450: a role for P4502C9 in the etiology of (s)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59.
100. Grasela T, Antal E, Ereshefsky L. An evaluation of population pharmacokinetics in therapeutic trials, II: detection of a drug-drug interaction. Clin Pharmacol Ther. 1987;42:433-441.
101. Preskorn S, Alderman J, Chung M. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994; 14:90-98.
102. Kurtz D, Bergstrom R, Goldberg M, Cerimale B. Drug interaction between sertraline and desipramine or imipramine. J Clin Pharmacol. 1994; 34:1009-1033. Abstract.
103. Rapeport W, Williams S, Muirhead D, Dewland P, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57(suppl 1):20-23.
104. Rapeport W, Muirhead D, Williams S, Cross M, Wesnes K. Absence of effect of sertraline on the phamacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry. 1996;57(suppl 1):24-28.